Literature DB >> 15347645

Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior.

Zhiyong Mi1, Hongtao Guo, Philip Y Wai, Chengjiang Gao, Junping Wei, Paul C Kuo.   

Abstract

Cancer progression depends on an accumulation of metastasis-supporting cell signaling molecules, which target signal transduction pathways and, ultimately, gene expression. One such molecule, osteopontin (OPN), represents a key molecular signaling event in tumor progression and metastasis. However, the transcriptional regulatory mechanisms that underlie OPN expression in the setting of breast cancer have not been well studied. In this regard, we have examined the differential transcriptional regulation of OPN in the murine mammary epithelial tumor cell lines, 4T1 and 4T07, which are sublines derived from the parental population of 410.4 cells from Balb/cfC3H mice. These lines are phenotypically heterogeneous in their metastatic behavior. 4T1 hematogenously metastasizes to the lung, liver, bone, and brain, whereas 4T07 is highly tumorigenic but fails to metastasize. The tumor growth and metastatic spread of 4T1 cells closely mimics stage IV breast cancer. We demonstrate that a Ras-independent, phosphoinositide-3 kinase-dependent, c-Jun N-terminal kinase-dependent phosphorylation of c-Jun results in binding of an AP-1 c-Jun homodimer to the OPN promoter in 4T1 cells. This differential up-regulation of OPN gene transcription and protein expression in 4T1 cells conveys in vitro correlates of a metastatic phenotype. These results provide new insight into the transcriptional regulation of OPN as a key mediator of metastatic behavior in malignancy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15347645     DOI: 10.1074/jbc.M407952200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Tumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway.

Authors:  Xuesong Qian; Jidong Zhang; Jianguo Liu
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

2.  Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435.

Authors:  Lalita A Shevde; Rajeev S Samant; Jason C Paik; Brandon J Metge; Ann F Chambers; Graham Casey; Andra R Frost; Danny R Welch
Journal:  Clin Exp Metastasis       Date:  2006-07-09       Impact factor: 5.150

3.  Differential expression of intracellular and secreted osteopontin isoforms by murine macrophages in response to toll-like receptor agonists.

Authors:  Wei Zhao; Lijuan Wang; Lei Zhang; Chao Yuan; Paul C Kuo; Chengjiang Gao
Journal:  J Biol Chem       Date:  2010-04-28       Impact factor: 5.157

4.  Phosphorylation of Ser158 regulates inflammatory redox-dependent hepatocyte nuclear factor-4alpha transcriptional activity.

Authors:  Hongtao Guo; Chengjiang Gao; Zhiyong Mi; Philip Y Wai; Paul C Kuo
Journal:  Biochem J       Date:  2006-03-01       Impact factor: 3.857

Review 5.  Studying non-mammalian models? Not a fool's ERRand!

Authors:  Pierre-Luc Bardet; Vincent Laudet; Jean-Marc Vanacker
Journal:  Trends Endocrinol Metab       Date:  2006-03-31       Impact factor: 12.015

6.  Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.

Authors:  Anandi Sawant; Jessy Deshane; Joel Jules; Carnella M Lee; Brittney A Harris; Xu Feng; Selvarangan Ponnazhagan
Journal:  Cancer Res       Date:  2012-12-14       Impact factor: 12.701

Review 7.  CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

Authors:  Dandan Lv; Yan Zhang; Ha-Jeong Kim; Lixing Zhang; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2013-02-04       Impact factor: 11.530

8.  RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer.

Authors:  Sirisha Emani; Jinping Zhang; Lucie Guo; Hongtao Guo; Paul C Kuo
Journal:  Surgery       Date:  2008-04-18       Impact factor: 3.982

9.  Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2.

Authors:  Xuesong Qian; Ling Gu; Huan Ning; Yanping Zhang; Eddy C Hsueh; Mingui Fu; Xiaoyu Hu; Lin Wei; Daniel F Hoft; Jianguo Liu
Journal:  J Immunol       Date:  2013-05-03       Impact factor: 5.422

10.  Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility.

Authors:  Silvia Giampieri; Cerys Manning; Steven Hooper; Louise Jones; Caroline S Hill; Erik Sahai
Journal:  Nat Cell Biol       Date:  2009-10-18       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.